- Entry level
- No Education
- Salary to negotiate
Global Product Strategy (GPS) drives Roche’s strategy and portfolio of products - from research through to patients. As a member of GPS, you will be part of a truly international group who collaborates with functions and affiliates worldwide to shape the future of medicine.
- We currently have multiple Integrated Strategy Leader (iSL) openings at our Basel-based headquarters -
As the iSL, you are the global commercialization accountable person for establishing a new disease area in ophthalmology, leading a fit-for-purpose team (iSquad) that includes cross-functional leaders representing key markets, and from global Access, Medical, Marketing and potentially other functions as you judge appropriate to the business needs. As a LCT member, you are accountable for the business globally ensuring timely, accurate and meaningful representation of the iSquad at the LCT.
You define the composition of the iSquad (i.e. global functional and affiliate representatives) and craft culture and set behavioral norms and expectations to build conditions for the operating principles of the model to flourish.
You embody servant leadership, developing all iSquad members through mentoring and feedback. You set the tone for a development and people-focused organization and collaborate with functional leadership to share feedback and ensure optimal success for all team members. You also lead a team of direct reports (GMM, GMaL, and GMLL if relevant).
You lead in the co-creation of a single integrated strategic plan (ISP), incorporating input from Marketing, Medical Affairs and Access and/or other teams as required., integrating cross-functional considerations to ensure our development and commercialization plans improve both patient benefit and business value of PDS and productively implement globally.
As an iSL, you are primarily accountable for:
To act as a single point of contact for International Heads (US, I-8, SMC leadership) and PLT regarding commercialization strategy
Direct Interface to the leadership (GMs/PSDs/IFLs) of the International 8 (Canada, Germany, France, Spain, Italy, UK, China, Brazil) and US (Franchise Heads/Squad Leads/ Marketing Directors):
Ensure the ISP will improve patient and business value in US and I-8.
Define success metrics and advise US and I-8 leadership on appropriate resource investments to implement the strategy. Influence in-market implementation plans to be consistent with the integrated strategy. Co-create solutions and define appropriate trade-offs where the strategy may not be flawless for a local market. Advise GM on resources and trade-offs for achieving local targets.
Define the brand, ambition and work dedicated with US and I-8 leadership to achieve or exceed business targets. Approve and evolve leading and lagging strategy and execution indicators by key market to identify new opportunities or enable course corrections. Be a sounding board and constructive challenger to their US and I8 partners.
Review and approve 3-year revenue forecast package guidance for key markets and develop assumptions plus assess and approve the output of 10-year probabilistic forecasting. Inform quarterly qualitative insights into CY+1 business outlook performance drivers, opportunities and challenges.
Develop, approve, and evaluate a global P&L for key opportunities to evolve global strategies and influence local resource allocation/mix to improve value. Develop and handle the global budget.
Overseeing and ensuring timely, useful communications to all markets (US and I-8), even those not sitting on iSquad.
Wide strategic scope:
Lead the co-creation of the global, integrated marketing, access, medical strategy, i.e., the Integrated Strategic Plan (ISP), together with their iSquad, that fully integrates cross-functional considerations and identify when this strategy, or parts thereof, should be updated given external or internal events or material new information considerations to improve patient and business value.
Identify and dedicatedly handle risks and trade-offs should the strategy not be optimal for a particular market.
Represent the integrated strategic perspective on development and commercialization topics to the LCT as a key standing member.
Consider and optimize brand strategies to support broader disease area and other enterprise goals.
Lead critical strategic projects for the disease area franchise and/or brand in close alignment with LCT.
Develop and approve global positioning, branding guidelines,
About the company
Roche is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.
The company headquarters are located in Basel and the company has many pharmaceutical and diagnostic sites around the world – including: Tucson, AZ; Pleasanton, CA; Vacaville, California, Oceanside, California, Branchburg, NJ; Indianapolis, Indiana; Florence, South Carolina; and Ponce, Puerto Rico in the US; Welwyn Garden City and Burgess Hill in the UK; Clarecastle in Ireland; Mannheim and Penzberg in Germany; Mississauga and Laval in Canada; Shanghai in China; Mumbai & Hyderabad in India; São Paulo and Rio de Janeiro, Brazil; Segrate, Milan in Italy; Johannesburg in South Africa; Karachi, Islamabad and Lahore in Pakistan. There are 26 manufacturing sites worldwide.